Loading page…

Glaxosmithkline Pharmaceuticals Limited (GLAXO) · mywealthgrid

About

Glaxosmithkline Pharmaceuticals is an Indian pharmaceutical company with a market cap of ₹45,548 Cr, maintaining strong profitability (34.26% OPM) and a fortress balance sheet (zero debt, D/E = 0). However, it is valued expensively at a PE of 42.64 with minimal recent price appreciation (0.42% 1-year return) amid flat revenue trends.

Face value: ₹10

Market cap

₹46,942 Cr

P/E

43.9×

P/B

20.7×

Dividend yield

3.6%

ROE

49.1%

ROCE

58.5%

Debt / equity

OPM

34.3%

EPS (TTM)

₹63.1

Book value

₹133.8

52-week high

₹3,106.4

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Expensive valuation: PE of 42.64 against only 0.42% 1-year return provides limited margin of safety; earnings must accelerate significantly to justify the current price
Flat revenue trajectory: quarterly revenues range ₹924–₹995 Cr with no visible growth over recent quarters
Recent margin compression: Jun 2026 OPM of 31.49–31.71% is 3–4 percentage points below prior quarters' 35%+ range; verify cost inflation, pricing pressure, or product mix drivers
Minority-shareholder risk: 75% promoter ownership concentrates control; verify board independence and capital allocation practices

Generated analysis · source review pending

Growth drivers

Zero debt (D/E = 0) and 49.11% ROE provide balance-sheet capacity to accelerate investment, but recent corporate events show only dividends, no acquisitions or capex announcements; verify if management is pursuing growth or maintaining the current model
Operating margins at 31–35% range create price flexibility, though Jun 2026 compression to 31% signals cost pressures; verify whether margin recovery is achievable through operational improvements or pricing adjustments
Indian pharmaceutical sector grows with demographics and healthcare spending, but this company's flat revenues (₹924–₹995 Cr) suggest limited share capture; verify market positioning and addressable opportunity

Generated analysis · source review pending

₹2,771.1+3.7%1Y

Beta

0.84

Moves with the index

Volatility (1y)

25.2%

Annualised, daily returns

RSI (14)

42.5

Neither overbought nor oversold

Rel. strength (1y)

-7.6%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Strong return on equity of 44.1% (3-yr avg)
+High return on capital employed of 55.2%
+Healthy operating margin of 34.3%
+Profit CAGR of 23.7% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 508.5×
+Dividend yield of 3.6%
+High promoter holding of 75% with no pledge

Cons

−Modest revenue growth of 3.6% a year over the last 5 years
−Trading at 20.7× book value

Research score

Structured signal from quality, growth, valuation and momentum.

54/100

Business quality

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 150 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,896	3,128	3,224	3,199	3,278	3,252	3,454	3,749	3,822
COGS	1,241	1,358	1,308	1,313	1,356	1,285	1,335	1,391	1,351
Gross profit	1,654	1,770	1,917	1,886	1,922	1,967	2,119	2,358	2,471
	1,149	1,169	1,259	1,191	1,160	1,163	1,210	1,181	1,161
	506	601	657	695	762	804	909	1,177	1,309
OPM %	17.5%	19.2%	20.4%	21.7%	23.2%	24.7%	26.3%	31.4%	34.3%
Depreciation	38	49	83	79	68	66	70	67	66
Interest	0	1	6	4	2	2	2	1	3
	72	131	-262	-62	1,401	103	-21	151	166
Profit before tax	540	683	306	551	2,093	839	816	1,260	1,406
Tax	189	237	213	192	398	229	226	332	370
Tax %	35.1%	34.8%	69.5%	34.9%	19%	27.3%	27.7%	26.4%	26.3%
	351	445	93	358	1,695	611	590	928	1,036
PAT margin %	12.1%	14.2%	2.9%	11.2%	51.7%	18.8%	17.1%	24.7%	27.1%
EPS (₹)	—	—	5.5	21.1	100	36.1	34.8	54.5	54.5
EPS adjusted (₹)	—	—	5.5	21.1	100	36.1	34.8	54.8	61.2
	—	—	727.3%	141.9%	90%	88.8%	91.9%	99%	104.5%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	169	169	169	169	169	169	169
Reserves	1,651	—	2,494	1,572	1,608	1,782	2,098
Minority interest	—	—	—	—	—	—	17
	0	—	0	0	0	0	0
	1,313	—	1,970	1,585	1,779	2,157	2,039
Total equity & liabilities	3,133	—	4,633	3,327	3,557	4,108	4,324
	717	386	329	329	320	283	280
CWIP	120	—	31	20	14	14	33
Investments	—	—	367	519	814	1,119	1,392
	2,296	—	3,907	2,458	2,408	2,692	2,618
Total assets	3,133	—	4,633	3,327	3,557	4,108	4,324

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	56.6%	59.4%	59%	58.6%

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%
	2.5%	2.93%	3.48%	4.02%	4.36%	4.5%	4.52%	4.89%	4.8%	4.64%	4.62%	4.79%
	10.01%	8.64%	7.9%	7.5%	7.34%	7.3%	7.79%	7.7%	7.75%	7.7%	7.68%	7.8%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	12.49%	13.43%	13.62%	13.48%	13.3%	13.2%	12.69%	12.41%	12.45%	12.66%	12.7%	12.41%
No. of shareholders	—	—	—	—	—	—	—	—	1,22,904	1,22,460	1,21,763	1,26,087

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 13 fund houses

Held by these funds

4.1%

of the company's equity

All mutual funds

4.87%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

67 schemes · 13 fund houses

		Shares
Midcap Fund	SBI Mutual Fund	11.8 L	359.91	1.47%	0.697%	-20,000
Portfolio of Kotak Large & Mid Cap FundNEW	Kotak Mahindra Mutual Fund	11 L	335.51	1.04%	0.649%	—
PHARMA FUND	Nippon India Mutual Fund	10.29 L	314	3.31%	0.608%	+1.01 L
Growth Mid Cap FundNEW	Nippon India Mutual Fund	5.59 L	170.5	0.33%	0.33%	—
Dividend Yield Fund	SBI Mutual Fund	4.5 L	137.25	1.6%	0.266%	-0
Flexi Cap Fund	Bajaj Finserv Mutual Fund	3.36 L	102.39	1.18%	0.198%	-0
AGGRESSIVE HYBRID FUND	Tata Mutual Fund	2.5 L	76.25	1.87%	0.148%	-65,000
Mid Cap FundNEW	Helios Mutual Fund	1.68 L	51.35	2.3%	0.099%	—

1–8 of 67

1 / 9

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

113 announcementsExport CSV

15 Sept 2026, 12:49 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Postal Ballot PDF

Loading announcements…

16 deals · 19 Sept 2022 – 17 Oct 2022

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	80,615	₹1,378.65	₹11.11 Cr
17 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	80,615	₹1,378.65	₹11.11 Cr
17 Oct 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	BSE	Buy	11,841	₹1,378.65	₹1.63 Cr
17 Oct 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	BSE	Sell	11,841	₹1,378.65	₹1.63 Cr
11 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	77,734	₹1,393.45	₹10.83 Cr
11 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	77,734	₹1,393.45	₹10.83 Cr
11 Oct 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	BSE	Sell	11,417	₹1,393.45	₹1.59 Cr
11 Oct 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	BSE	Buy	11,417	₹1,393.45	₹1.59 Cr
3 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	NSE	Sell	77,439	₹1,424.40	₹11.03 Cr
3 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	NSE	Buy	77,439	₹1,424.40	₹11.03 Cr

1–10 of 16

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Date	Category	Subject	Filing
15 Sept 2026, 12:49 pm	AGM/EGM Postal Ballot	Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot	PDF
15 Sept 2026, 12:47 pm	AGM/EGM Postal Ballot	GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report	PDF
2 Sept 2026, 11:29 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
1 Sept 2026, 3:31 pm	AGM/EGM Postal Ballot	Corrigendum To The Notice Of Postal Ballot Dated August 3, 2026	PDF
26 Aug 2026, 2:39 pm	Company Update General	Volume Movement Letter	PDF
26 Aug 2026, 2:03 pm	Company Update Clarification	Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd	—
19 Aug 2026, 5:26 pm	Company Update General	Disclosure Under Regulation 30	PDF
14 Aug 2026, 4:37 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

₹ Cr	Mar 2018	Mar 2019	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	473	399	578	811	484	582	1,290	903
	-104	-143	419	-406	808	9	-46	397
	-307	-358	-696	-524	-1,543	-561	-769	-737
Net cash flow	62	-102	300	-119	-251	29	475	563
Free cash flow	—	—	534	776	440	551	1,267	848
CFO / Operating profit %	93.5%	66.5%	83.1%	106.4%	60.2%	64.1%	109.6%	69%

Leverage
Current ratio	—	1.74	—	2.18	2.04	1.98	1.89	2.13

Return ratios
Return on assets %	—	3%	—	36.6%	18.4%	16.6%	22.6%	24%

Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

22

1

1

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Working capital
Receivable days	—	11	—	23	22	23	28	26

Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Ratio timeline

Quarterly record

Annual reports

Investor Presentation and earnings call

Dividends22

Board meetings1

Bonus issues1

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

22

1

1